These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38653344)

  • 21. Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.
    Paller AS; Pinter A; Wine Lee L; Aschoff R; Zdybski J; Schnopp C; Praestgaard A; Bansal A; Shumel B; Prescilla R; Bastian M
    Adv Ther; 2024 Mar; 41(3):1046-1061. PubMed ID: 38194047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registry.
    Kamphuis E; Loman L; Han HL; Romeijn GLE; Politiek K; Schuttelaar MLA
    Contact Dermatitis; 2023 May; 88(5):351-362. PubMed ID: 36621910
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Efficacy and safety of dupilumab in the treatment of moderate to severe atopic dermatitis].
    Wang JY; Zhou BJ; Cao QZ; Peng C; Chen ML; Chen X; Li J
    Zhonghua Yi Xue Za Zhi; 2024 Aug; 104(30):2810-2816. PubMed ID: 39085148
    [No Abstract]   [Full Text] [Related]  

  • 24. Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study.
    Johansson EK; Ivert LU; Bradley B; Lundqvist M; Bradley M
    BMC Dermatol; 2020 Sep; 20(1):8. PubMed ID: 32962676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.
    Bansal A; Simpson EL; Paller AS; Siegfried EC; Blauvelt A; de Bruin-Weller M; Corren J; Sher L; Guttman-Yassky E; Chen Z; Daizadeh N; Kamal MA; Shumel B; Mina-Osorio P; Mannent L; Patel N; Graham NMH; Khokhar FA; Ardeleanu M
    Am J Clin Dermatol; 2021 Jan; 22(1):101-115. PubMed ID: 33481203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2).
    Thaçi D; L Simpson E; Deleuran M; Kataoka Y; Chen Z; Gadkari A; Eckert L; Akinlade B; Graham NMH; Pirozzi G; Ardeleanu M
    J Dermatol Sci; 2019 May; 94(2):266-275. PubMed ID: 31109652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study.
    Patruno C; Fabbrocini G; Longo G; Argenziano G; Ferrucci SM; Stingeni L; Peris K; Ortoncelli M; Offidani A; Amoruso GF; Talamonti M; Girolomoni G; Grieco T; Iannone M; Nettis E; Foti C; Rongioletti F; Corazza M; Veneri MD; Napolitano M;
    Am J Clin Dermatol; 2021 Jul; 22(4):581-586. PubMed ID: 33725337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS.
    Silverberg JI; Yosipovitch G; Simpson EL; Kim BS; Wu JJ; Eckert L; Guillemin I; Chen Z; Ardeleanu M; Bansal A; Kaur M; Rossi AB; Graham NMH; Patel N; Gadkari A
    J Am Acad Dermatol; 2020 Jun; 82(6):1328-1336. PubMed ID: 32135208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
    Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
    Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multicenter Canadian case series of pediatric patients less than 12 years of age with moderate-to-severe atopic dermatitis treated with dupilumab.
    Martinez-Cabriales S; Marcoux D; Liy-Wong C; Prajapati VH; Sibbald C; Cunningham N; Lansang P; Tonkin R; Joseph M; Wong L; Spring S; Gavigan G; Ramien M
    Pediatr Dermatol; 2024; 41(1):5-11. PubMed ID: 37906120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials.
    Alexis AF; Rendon M; Silverberg JI; Pariser DM; Lockshin B; Griffiths CE; Weisman J; Wollenberg A; Chen Z; Davis JD; Li M; Eckert L; Gadkari A; Shumel B; Rossi AB; Graham NM; Ardeleanu M
    J Drugs Dermatol; 2019 Aug; 18(8):804-813. PubMed ID: 31424712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis.
    Yosipovitch G; de Bruin-Weller M; Armstrong A; Wu JJ; Herranz P; Thaçi D; Delevry D; Bagousse GB; Zhang R; Shumel B; Rossi AB; Chao J
    Dermatol Ther (Heidelb); 2021 Dec; 11(6):2147-2157. PubMed ID: 34714527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study.
    Deleuran M; Thaçi D; Beck LA; de Bruin-Weller M; Blauvelt A; Forman S; Bissonnette R; Reich K; Soong W; Hussain I; Foley P; Hide M; Bouaziz JD; Gelfand JM; Sher L; Schuttelaar MLA; Wang C; Chen Z; Akinlade B; Gadkari A; Eckert L; Davis JD; Rajadhyaksha M; Staudinger H; Graham NMH; Pirozzi G; Ardeleanu M
    J Am Acad Dermatol; 2020 Feb; 82(2):377-388. PubMed ID: 31374300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dupilumab in Elderly Patients With Severe Atopic Dermatitis.
    Russo F; Milanesi N; Cartocci A; Bruzziches F; Tronconi G; Lazzeri L; D'erme AM; Bagnoni G; Gola M; Cinotti E; Rubegni P; Flori ML
    Dermatitis; 2021 Oct; 32(1S):S24-S27. PubMed ID: 33332865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of dupilumab in chronic prurigo and chronic idiopathic pruritus: a systematic review of current evidence and analysis of response predictors.
    Gael M; Adam T; Mariano-Bourin M; Bursztejn AC
    J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):1541-1551. PubMed ID: 35569006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient-Reported Outcome Measures in Atopic Dermatitis and Chronic Hand Eczema in Adults.
    Barrett A; Hahn-Pedersen J; Kragh N; Evans E; Gnanasakthy A
    Patient; 2019 Oct; 12(5):445-459. PubMed ID: 31270775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic treatments for eczema: a network meta-analysis.
    Sawangjit R; Dilokthornsakul P; Lloyd-Lavery A; Lai NM; Dellavalle R; Chaiyakunapruk N
    Cochrane Database Syst Rev; 2020 Sep; 9(9):CD013206. PubMed ID: 32927498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
    Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
    Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis.
    Yosipovitch G; Reaney M; Mastey V; Eckert L; Abbé A; Nelson L; Clark M; Williams N; Chen Z; Ardeleanu M; Akinlade B; Graham NMH; Pirozzi G; Staudinger H; Plaum S; Radin A; Gadkari A
    Br J Dermatol; 2019 Oct; 181(4):761-769. PubMed ID: 30729499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab - a cross-sectional study from the BioDay registry.
    Oosterhaven JAF; Spekhorst LS; Zhang J; Voorberg AN; Romeijn GLE; Boesjes CM; de Graaf M; de Bruin-Weller MS; Schuttelaar MLA
    J Dermatolog Treat; 2022 Jun; 33(4):1986-1989. PubMed ID: 34151695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.